Sector Watch: Healthcare - May 11 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $106.58 +2.85 2.75% | XBI: $91.65 +2.61 2.93% | Updated May 11, 2018 04:26 PM
HEALTHCARE STOCKS - TOP GAINERS | ||||
---|---|---|---|---|
OMER Omeros $1.0B |
19.89+3.76 4.0 M 4.1x |
23% | ||
AST Asterias Biotherapeutics $81.7M |
1.45+0.20 320.3 K 2.1x |
16% | ||
SGYP Synergy Pharmaceuticals $477.6M |
1.89+0.26 12.6 M 3.9x |
16% | ||
SUPN52WH Supernus Pharmaceuticals $2.8B |
57.05+7.15 2.7 M 4.2x |
14% | ||
VSTM Verastem $243.2M |
4.93+0.56 1.9 M 1.7x |
13% |
HEALTHCARE STOCKS - TOP LOSERS | ||||
---|---|---|---|---|
XON Intrexon $1.9B |
14.98-3.66 5.3 M 4.4x |
-20% | ||
FATE Fate Therapeutics $485.0M |
9.31-1.65 1.8 M 3.7x |
-15% | ||
QHC Quorum Health $200.3M |
5.49-0.71 715.4 K |
-11% | ||
CERC Cerecor $111.2M |
3.50-0.39 434.1 K 2.4x |
-10% | ||
ALIM52WL Alimera Sciences $62.4M |
0.82-0.09 413.4 K 2.9x |
-10% |
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Global Celiac Disease Market Spotlight 2018 - Key Pipeline Drugs, Clinical Trials, Upcoming Events, Patent Information, a 10-Year Disease Prevalence Forecast, and Licensing & Acquisition Deals - ResearchAndMarkets.com | Business Wire [businesswire.com]Cerecor Reports First Quarter 2018 Financial Results [globenewswire.com]
Quorum Health Corporation to Participate in May Healthcare Conferences | Business Wire [businesswire.com]
Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results and Business Update | Business Wire [businesswire.com]
Omeros Corporation Reports First Quarter 2018 Financial Results | Business Wire [businesswire.com]
BioTime Reports First Quarter Results and Recent Corporate Accomplishments | Business Wire [businesswire.com]
Intrexon Announces First Quarter 2018 Financial Results [prnewswire.com]
Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update [globenewswire.com]
Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights [globenewswire.com]
AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018 [globenewswire.com]
Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue [globenewswire.com]
Quorum Health Corporation Announces First Quarter 2018 Financial and Operating Results | EON: Enhanced Online News [businesswire.com]
Irritable Bowel Syndrome Drug Development - 2018 Pipeline Analysis - ResearchAndMarkets.com | Business Wire [businesswire.com]
2018 Constipation Drug Development Pipeline Analysis - ResearchAndMarkets.com | Business Wire [businesswire.com]
2018 Celiac (Coeliac) Disease Drug Development- Pipeline Analysis Report - ResearchAndMarkets.com | Business Wire [businesswire.com]
Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results [prnewswire.com]
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results [globenewswire.com]
Attention Deficit Hyperactivity Disorder (ADHD): Disease Insights & Market Forecasts to 2024 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Stock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink [prnewswire.com]
Stock Performance Review on Biotech Industry -- Neptune Technologies & Bioressources, NewLink Genetics, OHR Pharma, and Omeros [prnewswire.com]
Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018 | Business Wire [businesswire.com]
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Business Wire [businesswire.com]
Global Cell Therapy Market, Price, Product & Clinical Pipeline Outlook 2024: A $25 Billion Opportunity - ResearchAndMarkets.com | Business Wire [businesswire.com]
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [businesswire.com]
Hercules Capital Announces First Quarter 2018 Financial Results and Quarterly Distribution of $0.31 per Share | Business Wire [businesswire.com]
Schizophrenia: Epidemiology Overview and Insights to 2024 - ResearchAndMarkets.com | Business Wire [businesswire.com]
Schizophrenia Market Intelligence Review and Insights, 2018 Report - ResearchAndMarkets.com | Business Wire [businesswire.com]
Verastem Oncology Reports First Quarter 2018 Financial Results [businesswire.com]
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results [globenewswire.com]
Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day | Business Wire [businesswire.com]
Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, [prnewswire.com]
Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day [businesswire.com]
Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus Pharma [prnewswire.com]
Quorum Health Corporation Announces First Quarter 2018 Earnings Release & Conference Call Schedule | Business Wire [businesswire.com]
Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights Nasdaq:FCSC [globenewswire.com]
Verastem Oncology Reports First Quarter 2018 Financial Results | Business Wire [businesswire.com]
AgeX Announces NIH Grant Award | Business Wire [businesswire.com]
Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10 [globenewswire.com]
Synthetic Biology Market Overview, 2018-2023 - Profiles of 36 Companies with Contact Details for 200+ Companies [prnewswire.com]
Avadel Pharmaceuticals Reports First Quarter 2018 Results [globenewswire.com]
Synthetic Biology Market, 2023 [globenewswire.com]
BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO | Business Wire [businesswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.